GILD लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 54 min ago

@ $64.70

जारी किया गया: 3 May 2024 @ 21:13

वापसी: -0.36%

पिछला सिग्नल: May 3 - 19:05

पिछला सिग्नल: खरीदें

वापसी: -0.25 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 22:08):
Our systems believe the stock currently is undervalued by 0.20% compare to its pairs and should correct upwards.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
आज की मात्रा	2.85M
औसत मात्रा	7.40M
बाजार मूल्य	80.39B
EPS	$0 ( 2024-04-25 )
अगली कमाई की तारीख	( $1.590 ) 2024-08-01
Last Dividend	$0.750 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	179.08
ATR14	$1.200 (1.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Telman Deborah H	Sell	515	Restricted Stock Unit
2024-04-25	Telman Deborah H	Buy	515	Common Stock
2024-04-25	Telman Deborah H	Sell	158	Common Stock
2024-04-01	Parsey Merdad	Sell	2 000	Common Stock
2024-03-28	Lofton Kevin E	Buy	34	Phantom Stock

INSIDER POWER
62.13
Last 99 transactions
Buy: 1 291 503 \| Sell: 311 301

सहसंबंध (AI algo v.1.1b): Undervalued: 0.20% $64.60 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: -0.35 (neutral)

छोटा: 0.99 (very strong)

Signal:(45) Expect same movement, but be aware

Gilead Sciences Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
NUTX	0.956
TROO	0.95
PRTA	0.943
SINT	0.941
RNW	0.931
APLD	0.93
DCFC	0.928
PTON	0.928
BNTX	0.926
MRBK	0.923

10 सबसे अधिक नकारात्मक सहसंबंध
FAAR	-0.946
ADES	-0.941
BOCN	-0.928
RAM	-0.921
AMTBB	-0.917
CITE	-0.917
BCSA	-0.915
XENT	-0.915
XFIN	-0.914
IXAQ	-0.914

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Gilead Sciences Inc सहसंबंध - मुद्रा/वस्त्र

0.00
( neutral )

-0.45
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.49
( neutral )

0.43
( neutral )

Gilead Sciences Inc वित्तीय

Annual	2023
राजस्व:	$27.12B
सकल लाभ:	$21.15B (77.99 %)
EPS:	$4.54

FY	2023
राजस्व:	$27.12B
सकल लाभ:	$21.15B (77.99 %)
EPS:	$4.54

FY	2022
राजस्व:	$27.28B
सकल लाभ:	$21.62B (79.26 %)
EPS:	$3.66

FY	2021
राजस्व:	$27.31B
सकल लाभ:	$20.70B (75.82 %)
EPS:	$4.96

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend King

Dividend Sustainability Score: 9.34 - good (93.42%) | Divividend Growth Potential Score: 6.34 - Stable (26.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.750	2023-12-14
Next Dividend	$0	N/A
Payout Date	2023-12-28
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	$21.49	--
Avg. Dividend % Per Year	2.65%	--
Score	5.26	--
Div. Sustainability Score	9.34
Div.Growth Potential Score	6.34
Div. Directional Score	7.84	--

Next Divdend (Est)
(2024-07-01)

$0.764 Estimate 39.70 %

Dividend Stability

0.79 Good

Dividend Score

5.26

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0176	1.500	9.65	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00860	1.200	9.71	10.00	[0 - 0.3]
returnOnEquityTTM	0.0232	1.500	-0.854	-1.280	[0.1 - 1]
payoutRatioTTM	5.87	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.980	0.800	-0.102	-0.0814	[1 - 3]
quickRatioTTM	1.084	0.800	8.33	6.66	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.459	-1.500	2.35	-3.53	[0 - 0.6]
interestCoverageTTM	9.53	1.000	7.58	7.58	[3 - 30]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.34	2.00	6.83	10.00	[0 - 20]
debtEquityRatioTTM	1.479	-1.500	4.08	-6.12	[0 - 2.5]
grossProfitMarginTTM	0.777	1.000	0.382	0.382	[0.2 - 0.8]
operatingProfitMarginTTM	0.336	1.000	5.28	5.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.488	0.800	-0.0824	-0.0659	[0.5 - 2]
Total Score				9.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	168.32	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0232	2.50	-0.549	-1.280	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.34	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	4.62	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	5.87	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.570	1.500	9.54	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.309	1.000	4.78	0	[0.1 - 0.5]
Total Score				6.34

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.